Ask AI

Capsule Summary Slidesets

Share

Program Content

Activities

  • TRANSCEND NHL 001
    TRANSCEND NHL 001: Phase I Study of Lisocabtagene Maraleucel in R/R LBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2019

  • ELEVATE TN
    ELEVATE TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2019

  • Frontline AVO in CLL
    Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab Combination Therapy in Previously Untreated CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2019

  • VEN+IBR in High-Risk CLL
    Venetoclax and Ibrutinib Combination Therapy for Treatment-Naive High-Risk CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2019

  • Phase II CAPTIVATE Study
    Phase II CAPTIVATE Trial of First-line Ibrutinib Plus Venetoclax in CLL/SLL: MRD Cohort Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2019

  • LOXO-305 in CLL/B-Cell NHL
    BRUIN: First-in-Human Phase I Trial Investigating Non-Covalent BTK Inhibitor LOXO-305 in Pretreated B-Cell Malignancies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2019

  • TRANSCEND CLL 004 Updates
    Phase I/II TRANSCEND CLL 004: Updated Results of Lisocabtagene Maraleucel in Patients With Relapsed/Refractory CLL or SLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2019

  • Mosunetuzumab in R/R NHL
    Phase I/Ib Study of Mosunetuzumab in Heavily Pretreated Patients With R/R B-Cell Non-Hodgkin Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2019

  • TRANSCEND NHL 001: PROs With Liso-Cel
    TRANSCEND NHL 001: Patient-Reported Outcomes With Liso-Cel in Patients With Relapsed/Refractory Aggressive B-Cell NHL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2019

  • KTE-X19 in R/R MCL
    Phase II ZUMA-2 Trial of KTE-X19 CAR T-Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2019

  • Real-world Axi-Cel Data
    Postmarketing Outcomes of CD19-Directed CAR T-Cell Agent Axicabtagene Ciloleucel for Treatment of Large B-Cell Lymphoma in the United States
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2019

Provided by

ProCE Banner

Supporters

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company